Baird’s Haemonetics HAE Stock Holding History

Baird’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,692	Closed	-$400K	–	1328
2014 Q4	$400K	Buy	+10,692	New	+$392K	﹤0.01%	1018
2014 Q3	–	Sell	-5,810	Closed	-$205K	–	1127
2014 Q2	$205K	Sell	5,810 -5,963	-51%	-$199K	﹤0.01%	1093
2014 Q1	$384K	Buy	11,773 +476	+4%	+$18.2K	0.01%	936
2013 Q4	$476K	Buy	11,297 +48	+0.4%	+$1.98K	0.01%	853
2013 Q3	$449K	Sell	11,249 -103	-0.9%	-$4.32K	0.01%	829
2013 Q2	$469K	Buy	+11,352	New	+$460K	0.01%	780

Other funds holding HAE

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baird's HAE Position: Q1 2015 in Review

Baird sold out of Haemonetics (HAE) in Q1 2015, closing a stake of 10,692 shares — an estimated $400K sold.

Baird first reported a position in HAE in Q2 2013 and held it in 6 quarters. The position peaked at $476K in Q4 2013. 169 funds tracked by Wall St. Rank hold HAE as of Q1 2015.

Baird reported no remaining Haemonetics position as of Q1 2015 after selling out during the quarter.
Baird sold 10,692 Haemonetics shares in Q1 2015, an estimated $400K.
Baird first reported a position in Haemonetics in Q2 2013 and held it in 6 quarters.
Baird's Haemonetics position peaked at $476K in Q4 2013.
169 funds tracked by Wall St. Rank held Haemonetics as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.